EP939 - Systemic Chemotherapy Followed Only by Cytoreductive Surgery As Treatment For Peritoneal Carcinomatosis Of Colorectal Origin

Tuesday, May 13, 2025

8:43 AM – 8:48 AM PT

ePoster Presenter(s)

VD

Valentina Durán Espinoza, MD, MSc

Resident
Pontificia Universidad Católica de Chile
Santiago, Region Metropolitana, Chile

All of the relevant financial relationships listed below have been mitigated.
This individual has no financial relationships with ineligible companies.

Author(s)

Carlos G. Morales, MD (he/him/his)

Resident
Complejo Asistencial Dr Sotero del Rio
Santiago, Region Metropolitana, Chile

All of the relevant financial relationships listed below have been mitigated.
This individual has no financial relationships with ineligible companies.
EM

Erik Manriquez, n/a

Attending Colorectal Surgeon
Hospital Sotero del Rio
Santiago, Region Metropolitana, Chile

Disclosure information not submitted.
GC

Gonzalo Carvajal, MD

Colorectal Surgeon
Complejo Asistencial Dr. Sótero del Río
Santiago, Region Metropolitana, Chile

Disclosure information not submitted.
PB

Pamela Briones Nuñez, MD

Colorectal Surgeon
Complejo Asistencial Doctor Sotero del Rio
Colina, Region Metropolitana, Chile

Disclosure information not submitted.
MC

Manuel Cabreras, MD

Surgeon
Complejo Asistencial Dr Sotero del Rio
Santiago, Region Metropolitana, Chile

Disclosure information not submitted.
RC

Richard Castillo, MD

Surgeon
Complejo Asistencial Dr Sotero del Rio
Santiago, Region Metropolitana, Chile

Disclosure information not submitted.
FM

Felipe A. Mena, Md

General Surgeon
Complejo Asistencial Dr Hospital Sotero del Rio
Santiago, Region Metropolitana, Chile

Disclosure information not submitted.
KB

Kaorys Barros, MD

Resident
Instituto de Cataluña Central
Manresa, Catalonia, Spain

Disclosure information not submitted.
AF

Angelo F. Fulle, MD

Colorectal Surgeon
Complejo Asistencial Dr Sotero del Rio
Santiago, Region Metropolitana, Chile

Disclosure information not submitted.
RK

Rodrigo Kusanovich, MD

Colorectal Surgeron
Complejo Asistencial Doctor Sotero del Rio
Santiago, Region Metropolitana, Chile

Disclosure information not submitted.

Senior Author(s)

FQ

Felipe Quezada-Diaz, MD

Colorectal Surgeon
Complejo Asistencial Doctor Sotero del Rio
Santiago, Region Metropolitana, Chile

All of the relevant financial relationships listed below have been mitigated.
This individual has no financial relationships with ineligible companies.

All of the relevant financial relationships listed below have been mitigated.

Valentina Durán Espinoza, MD, MSc: This individual has no financial relationships with ineligible companies.

Carlos G. Morales, MD: This individual has no financial relationships with ineligible companies.

Felipe Quezada-Diaz, MD: This individual has no financial relationships with ineligible companies.

Image or Table (Do Not add text here):

Purpose/Background: Peritoneal carcinomatosis is a poor prognostic factor in metastatic colorectal cancer. In recent decades, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a promising therapeutic approach. However, several studies have questioned the added benefit of HIPEC. This study presents a case series of patients with colorectal-origin peritoneal carcinomatosis, treated with systemic chemotherapy (SC) and CRS alone.

Methods/Interventions: This retrospective study included patients with peritoneal carcinomatosis of colorectal origin who were treated with SC and CRS alone between November 2016 and February 2024 at Complejo Asistencial Doctor Sótero del Río in Santiago, Chile. Patients with histology other than adenocarcinoma were excluded. Demographic and perioperative variables, including the Peritoneal Carcinomatosis Index (PCI), were recorded. Data were collected directly from electronic medical records.

Results/Outcomes: Twelve patients with a median age of 58 years (range 48.5–71.5) were included in the study. Tumor locations were as follows: 58.3% in the sigmoid colon (n=7), 33.3% in the rectosigmoid junction (n=4), and 8.3% in the ascending colon (n=1). All patients underwent SC , with 91% (n=10) completing full dose of SC prior to CRS. The median Peritoneal Cancer Index (PCI) was 12 (range 5–14), and complete cytoreduction (CCR 0–1) was achieved in all patients. At 30 days postoperatively, 30.8% (n=4) experienced major complications, and 15.4% (n=2) required surgical re-intervention. One patient (8.3%) died within 90 days post-surgery. After a median follow-up of 21.6 months (range 14.3–33.4), 50% of the patients were still alive.

Conclusion/Discussion: SC in association with CRS alone is a viable treatment option for peritoneal carcinomatosis of colorectal origin. However, further studies are needed to draw definitive conclusions and to better determine the optimal strategy of SC in this patient population.